Search results for " cyclooxygenase inhibitor"

showing 3 items of 3 documents

Role of cyclooxygenase pathways in bowel fibrotic remodelling in a murine model of experimental colitis

2022

Abstract Objective Gut fibrosis occurs under chronic inflammation. This study examined the effects of different cyclooxygenase (COX) inhibitors on fibrosis in the inflamed colon. Methods Colitis was induced by 2,4-dinitrobenzenesulfonic acid (DNBS) in albino male Sprague–Dawley rats. After 6, 12 and 18 days, macroscopic and microscopic damage, collagen and elastic fibre content were examined. At day 6, pro-fibrotic factors (collagen I and III, hydroxyproline, fibronectin, matrix metalloproteinase-2 and -9), transforming growth factor-beta (TGF-β) signalling [TGF-β, Ras homolog gene family member A (RhoA), phosphorylated small mother against decapentaplegic (pSMAD)-2 and -6] and peristalsis …

TGF-βPharmacologyfibrosis cyclooxygenase inhibitor gutinflammatory bowel diseasefibrosiscyclooxygenase inhibitorgutPharmaceutical ScienceSMADCyclooxygenaseJournal of Pharmacy and Pharmacology
researchProduct

Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. T…

2017

Background Type 2 diabetes mellitus (T2DM) is one of the most common causes of chronic kidney disease and kidney failure. It has been estimated that the annual decline of estimated glomerular filtration rate (eGFR) among patients with T2DM is approximately 2.0-2.5 mL min−1 y−1. Cyclooxygenase-dependent eicosanoids, such as 11-dehydro-thromboxane (Tx)B2, are increased in T2DM patients and are potentially involved in the regulation of renal blood flow. Animal models showed that cyclooxygenase inhibitors, such as aspirin, are associated with improvements in renal plasma flow and eGFR values. Hypothesis The primary end point of the LEDA trial is to evaluate the 1-year decline of eGFR in T2DM pa…

Time Factorskidney disease030204 cardiovascular system & hematologylaw.invention0302 clinical medicineRandomized controlled triallawClinical endpointMedicineRenal Insufficiency030212 general & internal medicineChronicKidneyAspirinkidney disease progressionclinical trialtrialPrognosisType 2 diabetes mellituAspirin; Cyclooxygenase Inhibitors; Diabetes Mellitus Type 2; Disease Progression; Dose-Response Relationship Drug; Double-Blind Method; Follow-Up Studies; Glomerular Filtration Rate; Humans; Prognosis; Renal Insufficiency Chronic; Time Factors; Cardiology and Cardiovascular Medicinemedicine.anatomical_structureAspirin; Cyclooxygenase Inhibitors; Diabetes Mellitus; Type 2; Disease Progression; Dose-Response Relationship; Drug; Double-Blind Method; Follow-Up Studies; Glomerular Filtration Rate; Humans; Prognosis; Renal Insufficiency; Chronic; Time Factors; Cardiology and Cardiovascular MedicineDisease Progressiontype 2 diabetesDrugSettore SECS-S/01 - StatisticaCardiology and Cardiovascular MedicineType 2Glomerular Filtration Ratemedicine.drugmedicine.medical_specialtyUrologyRenal functionDose-Response Relationship03 medical and health sciencesDouble-Blind MethodDiabetes MellitusHumansCyclooxygenase InhibitorsRenal Insufficiency Chronickidney disease kidney disease progression type 2 diabetes aspirin trialDose-Response Relationship DrugAspirinbusiness.industryrenal functionmedicine.diseaseSurgeryClinical trialDiabetes Mellitus Type 2Renal blood flowbusinessFollow-Up StudiesKidney disease
researchProduct

Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs

1997

International audience; The discovery of at least 2 cyclo-oxygenase (COX) isoenzymes, referred to as COX-1 and COX-2, has updated our knowledge of nonsteroidal anti-inflammatory drugs (NSAIDs). This has lead investigators to reconsider what can be awaited from this class of drugs. The 2 COX isoenzymes share structural and enzymatic similarities, but are specifically regulated at the molecular level and may be distinguished apart in their functions, although some physiological overlap between them does occur. The major goal in developing selective COX inhibitors is to improve NSAID tolerability. Classic NSAIDs preferentially inhibit COX-1 in vitro, but it appears hazardous to judge their gas…

[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionMESH: Prostaglandin-Endoperoxide SynthasesAnti-Inflammatory AgentsPharmacologyNabumetoneMESH: Cyclooxygenase InhibitorsPharmacotherapymedicineMESH : Anti-Inflammatory Agents Non-SteroidalAnimalsHumansPharmacology (medical)Cyclooxygenase InhibitorsMESH: AnimalsAdverse effectMESH: HumansMESH : Prostaglandin-Endoperoxide Synthasesbusiness.industryMESH : HumansAnti-Inflammatory Agents Non-SteroidalMESH : Cyclooxygenase InhibitorsMESH: Anti-Inflammatory Agents Non-SteroidalClinical trial[SDV.AEN] Life Sciences [q-bio]/Food and NutritionMeloxicamTolerabilityProstaglandin-Endoperoxide SynthasesMESH : AnimalsCyclo-oxygenaseNon-Steroidalbusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionNimesulidemedicine.drug
researchProduct